Alzheimer's disease (AD) is a neurodegenerative disease whose various pathophysiological aspects are still being investigated. Recently, it has been hypothesized that AD may be associated with a dysbiosis of microbes in the intestine. In fact, the intestinal flora is able to influence the activity of the brain and cause its dysfunctions.Given the growing interest in this topic, the purpose of this review is to analyze the role of antibiotics in relation to the gut microbiota and AD. In the first part of the review, we briefly review the role of gut microbiota in the brain and the various theories supporting the hypothesis that dysbiosis can be associated with AD pathophysiology. In the second part, we analyze the possible role of antibiotics in these events. Antibiotics are normally used to remove or prevent bacterial colonization in the human body, without targeting specific types of bacteria. As a result, broad-spectrum antibiotics can greatly affect the composition of the gut microbiota, reduce its biodiversity, and delay colonization for a long period after administration. Thus, the action of antibiotics in AD could be wide and even opposite, depending on the type of antibiotic and on the specific role of the microbiome in AD pathogenesis.Alteration of the gut microbiota can induce changes in brain activity, which raise the possibility of therapeutic manipulation of the microbiome in AD and other neurological disorders. This field of research is currently undergoing great development, but therapeutic applications are still far away. Whether a therapeutic manipulation of gut microbiota in AD could be achieved using antibiotics is still not known. The future of antibiotics in AD depends on the research progresses in the role of gut bacteria. We must first understand how and when gut bacteria act to promote AD. Once the role of gut microbiota in AD is well established, one can think to induce modifications of the gut microbiota with the use of pre-, pro-, or antibiotics to produce therapeutic effects.

Memory Clinic Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Viña J, Sanz-Ros J. Alzheimer’s disease: only prevention makes sense. Eur J Clin Invest. 2018;48(10):e13005. doi: 10.1111/eci.13005. PubMed DOI

Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19:687–700. doi: 10.1038/s41583-018-0067-3. PubMed DOI PMC

Xin SH, Tan L, Cao X, Yu JT, Tan L. Clearance of amyloid beta and tau in Alzheimer’s disease: from mechanisms to therapy. Neurotox. Res. 2018;34(3):733–748. doi: 10.1007/s12640-018-9895-1. PubMed DOI

Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer’s disease. J Alzheimer’s Dis. 2017;58:1–15. doi: 10.3233/JAD-161141. PubMed DOI

Gareau Mélanie G. Advances in Experimental Medicine and Biology. New York, NY: Springer New York; 2014. Microbiota-Gut-Brain Axis and Cognitive Function; pp. 357–371. PubMed

Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17 Available from: 10.1007/s11910-017-0802-6. PubMed

Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimer’s Dement. 2016;12:719–732. doi: 10.1016/j.jalz.2016.02.010. PubMed DOI

Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. J Nutr Biochem. 2018;61:111–128. doi: 10.1016/j.jnutbio.2018.07.010. PubMed DOI PMC

Daliri EB-M, Tango CN, Lee BH, Oh D-H. Human microbiome restoration and safety. Int J Med Microbiol. 2018;308:487–497. doi: 10.1016/j.ijmm.2018.05.002. PubMed DOI

Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10:735–742. doi: 10.1038/nrmicro2876. PubMed DOI

Wekerle H. The gut–brain connection: triggering of brain autoimmune disease by commensal gut bacteria. Rheumatology. 2016;55:ii68–ii75. doi: 10.1093/rheumatology/kew353. PubMed DOI

Briguglio M, Dell’Osso B, Panzica G, Malgaroli A, Banfi G, Zanaboni Dina C, et al. Dietary neurotransmitters: a narrative review on current knowledge. Nutrients. 2018;10:591. doi: 10.3390/nu10050591. PubMed DOI PMC

Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. 2017;46:77–89. doi: 10.1016/j.gtc.2016.09.007. PubMed DOI

Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:49. doi: 10.3389/fnins.2018.00049. PubMed DOI PMC

Wang HX, Wang YP. Gut microbiota-brain axis. Chin Med J (Engl). 2016. PubMed PMC

Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–209. PubMed PMC

Logsdon AF, Erickson MA, Rhea EM, Salameh TS, Banks WA. Gut reactions: how the blood–brain barrier connects the microbiome and the brain. Exp Biol Med. 2017;243:159–165. doi: 10.1177/1535370217743766. PubMed DOI PMC

Zac-Varghese S, Tan T, Bloom SR. Hormonal interactions between gut and brain. Discov Med. 2010;10(55):543–552. PubMed

Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv Exp Med Biol. 2014;817:373–403. doi: 10.1007/978-1-4939-0897-4_17. PubMed DOI

Links between gut microbes and depression strengthened. Nature. 2019;566(7742):7. PubMed

Galland L. The gut microbiome and the brain. J Med Food. 2014;17:1261–1272. doi: 10.1089/jmf.2014.7000. PubMed DOI PMC

Alam R, Abdolmaleky HM, Zhou J-R. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet Part B Neuropsychiatr Genet. 2017;174:651–660. doi: 10.1002/ajmg.b.32567. PubMed DOI PMC

Johnson KV-A, Foster KR. Why does the microbiome affect behaviour? Nat Rev Microbiol. 2018;16:647–655. doi: 10.1038/s41579-018-0014-3. PubMed DOI

Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut. 2010;60:307–317. doi: 10.1136/gut.2009.202515. PubMed DOI

Cox LM, Weiner HL. Microbiota signaling pathways that influence neurologic disease. Neurotherapeutics. 2018;15:135–145. doi: 10.1007/s13311-017-0598-8. PubMed DOI PMC

Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics. 2017;15:36–59. doi: 10.1007/s13311-017-0585-0. PubMed DOI PMC

Braakman HMH, van Ingen J. Can epilepsy be treated by antibiotics? J Neurol. 2018;265:1934–1936. doi: 10.1007/s00415-018-8943-3. PubMed DOI

Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2018;34:396–405. doi: 10.1002/mds.27581. PubMed DOI

Kong G, Cao K-AL, Judd LM, Li S, Renoir T, Hannan AJ. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 2018; Available from: 10.1016/j.nbd.2018.09.001. PubMed

Kirby T, Ochoa-Repáraz J. The gut microbiome in multiple sclerosis: a potential therapeutic avenue. Med Sci. 2018;6:69. PubMed PMC

DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139:136–153. doi: 10.1111/jnc.13607. PubMed DOI PMC

Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J Neurochem. 2015;136:457–474. doi: 10.1111/jnc.13411. PubMed DOI

Bagyinszky E, Van GV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci. 2017;376:242–254. doi: 10.1016/j.jns.2017.03.031. PubMed DOI

Wang M-M, Miao D, Cao X-P, Tan L, Tan L. Innate immune activation in Alzheimer’s disease. Ann Transl Med. 2018;6:177. doi: 10.21037/atm.2018.04.20. PubMed DOI PMC

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016. PubMed PMC

Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010;5(11):e13950. doi: 10.1371/journal.pone.0013950. PubMed DOI PMC

Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain. 2017;140(3):792–803. PubMed PMC

Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–1099. doi: 10.1038/ng.439. PubMed DOI

Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623–632. doi: 10.1016/j.ajhg.2008.10.008. PubMed DOI PMC

Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–1071. doi: 10.1016/j.cell.2015.01.049. PubMed DOI PMC

Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis. 2013;54:139–149. doi: 10.1016/j.nbd.2013.02.003. PubMed DOI

Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer’s disease risk gene cd33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–643. doi: 10.1016/j.neuron.2013.04.014. PubMed DOI PMC

Clark IA, Vissel B. Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br J Pharmacol. 2015;172:3714–3727. doi: 10.1111/bph.13181. PubMed DOI PMC

Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide. PLoS One. 2010;5:e9505. doi: 10.1371/journal.pone.0009505. PubMed DOI PMC

Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373(6514):523–527. doi: 10.1038/373523a0. PubMed DOI

Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014;124(5):307–321. doi: 10.3109/00207454.2013.833510. PubMed DOI

Dong Yuan, Li Xiaoheng, Cheng Jinbo, Hou Lin. Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target? International Journal of Molecular Sciences. 2019;20(3):558. doi: 10.3390/ijms20030558. PubMed DOI PMC

Pretorius E, Bester J, Kell DB. A bacterial component to Alzheimer’s-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis. 2016;53:1237–1256. doi: 10.3233/JAD-160318. PubMed DOI PMC

Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci China Life Sci [Internet]. Springer Nature. 2016;59:1006–1023. doi: 10.1007/s11427-016-5083-9. PubMed DOI

Ashraf Ghulam M., Tarasov Vadim V., Makhmutovа Alfiya, Chubarev Vladimir N., Avila-Rodriguez Marco, Bachurin Sergey O., Aliev Gjumrakch. The Possibility of an Infectious Etiology of Alzheimer Disease. Molecular Neurobiology. 2018;56(6):4479–4491. doi: 10.1007/s12035-018-1388-y. PubMed DOI

Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 2018;14:1602–1614. doi: 10.1016/j.jalz.2018.06.3040. PubMed DOI

Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–882. doi: 10.1016/j.jamda.2013.05.009. PubMed DOI

Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7 Available from: 10.1038/srep41802. PubMed PMC

Roubaud-Baudron C, Quadrio I, Krolak-Salmon P, Mégraud F, Salles N. Impact of chronic Helicobacter pylori infection on Alzheimer’s disease: preliminary results. Neurobiol Aging. 2011. PubMed

Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, et al. A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. 2015;22(12):1519–1525. doi: 10.1111/ene.12477. PubMed DOI

Wang Xiu-Lian, Zeng Ji, Yang Yang, Xiong Yan, Zhang Zhi-Hua, Qiu Mei, Yan Xiong, Sun Xu-Ying, Tuo Qing-Zhang, Liu Rong, Wang Jian-Zhi. Helicobacter pylori Filtrate Induces Alzheimer-Like Tau Hyperphosphorylation by Activating Glycogen Synthase Kinase-3β. Journal of Alzheimer's Disease. 2014;43(1):153–165. doi: 10.3233/JAD-140198. PubMed DOI

Pisa Di AR, Fernández-Fernández AM, Rábano A, Carrasco L. Polymicrobial infections in brain tissue from Alzheimer’s disease patients. Sci Rep. 2017;7(1):5559. doi: 10.1038/s41598-017-05903-y. PubMed DOI PMC

Zhao Y, Jaber VLW. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol. 2017;7:318. doi: 10.3389/fcimb.2017.00318. PubMed DOI PMC

Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–68. doi: 10.1016/j.neurobiolaging.2016.08.019. PubMed DOI

Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease: possible mechanisms and signposts. FASEB J. 2017;31(8):3216–3226. doi: 10.1096/fj.201700360. PubMed DOI

Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, et al. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis. 2015;211(2):230–237. doi: 10.1093/infdis/jiu437. PubMed DOI PMC

Bernstein HG, Keilhoff G, Dobrowolny HSJ. Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme’s implication for Alzheimer’s disease pathology? Eur Arch Psychiatry Clin Neurosci. 2019. PubMed

Lin WR, Casas I, Wilcock GK, Itzhaki RF. Neurotropic viruses and Alzheimer’s disease: a search for varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 2008. PubMed PMC

L H, O J, W B, J A, E S, H G, et al. Interaction between Cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer’s disease development. J Alzheimer’s Dis. 2018. PubMed

Maqsood R, Stone TW. The gut-brain axis, BDNF, NMDA and CNS disorders. Neurochem Res. 2016;41:2819–2835. doi: 10.1007/s11064-016-2039-1. PubMed DOI

Marques C, Meireles M, Faria A, Calhau C. High-fat diet–induced dysbiosis as a cause of neuroinflammation. Biol Psychiatry. 2016;80:e3–e4. doi: 10.1016/j.biopsych.2015.10.027. PubMed DOI

Li H, Sun J, Du J, Wang F, Fang R, Yu C, et al. Clostridium butyricum exerts a neuroprotective effect in a mouse model of traumatic brain injury via the gut-brain axis. Neurogastroenterol Motil. 2017;30:e13260. doi: 10.1111/nmo.13260. PubMed DOI

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200. doi: 10.1080/19490976.2015.1134082. PubMed DOI PMC

Caracciolo B, Xu W, Collins S, Fratiglioni L. Cognitive decline, dietary factors and gut–brain interactions. Mech Ageing Dev. 2014;136(137):59–69. doi: 10.1016/j.mad.2013.11.011. PubMed DOI

Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178–184. doi: 10.1038/nature11319. PubMed DOI

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2006;908:244–254. doi: 10.1111/j.1749-6632.2000.tb06651.x. PubMed DOI

Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep. 2016;6 Available from: 10.1038/srep30028. PubMed PMC

Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965–977. doi: 10.1038/nn.4030. PubMed DOI PMC

Ege MJ. The hygiene hypothesis in the age of the microbiome. Ann Am Thorac Soc. 2017;14:S348–S353. doi: 10.1513/AnnalsATS.201702-139AW. PubMed DOI

Browne TC, McQuillan K, McManus RM, O’Reilly J-A, Mills KHG, Lynch MA. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190:2241–2251. doi: 10.4049/jimmunol.1200947. PubMed DOI

Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242:52–59. doi: 10.1016/j.jneuroim.2011.11.005. PubMed DOI

Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Calvo MG, et al. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis. 2010;21:927–938. doi: 10.3233/JAD-2010-091696. PubMed DOI

Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139:1237–1251. doi: 10.1093/brain/awv408. PubMed DOI

Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, et al. Dramatic shifts in circulating cd4 but not cd8 t cell subsets in mild alzheimer’s disease. J Alzheimer’s Dis. 2009;17:91–103. doi: 10.3233/JAD-2009-1015. PubMed DOI

Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer’s disease: the enemy within. J Alzheimer’s Dis. 2008;13:393–405. doi: 10.3233/JAD-2008-13405. PubMed DOI

Laitinen MH, Ngandu T, Rovio S, Helkala E-L, Uusitalo U, Viitanen M, et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord. 2006;22:99–107. doi: 10.1159/000093478. PubMed DOI

Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906–1915. doi: 10.1136/gutjnl-2016-312297. PubMed DOI

Neuman H, Forsythe P, Uzan A, Avni O, Koren O. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol Rev. 2018; Available from: 10.1093/femsre/fuy018. PubMed

Fröhlich EE, Farzi A, Mayerhofer R, Reichmann F, Jačan A, Wagner B, et al. Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun. 2016;56:140–155. doi: 10.1016/j.bbi.2016.02.020. PubMed DOI PMC

Neufeld NH, Mohamed NS, Grujich N, Shulman K. Acute neuropsychiatric symptoms associated with antibiotic treatment of Helicobacter pylori infections. J Psychiatr Pract. 2017;23:25–35. doi: 10.1097/PRA.0000000000000205. PubMed DOI

Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat Commun. 2018;9 Available from: 10.1038/s41467-018-05336-9. PubMed PMC

Wang T, Hu X, Liang S, Li W, Wu X, Wang L, et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–717. doi: 10.3920/BM2014.0177. PubMed DOI

Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2010;23:255–e119. doi: 10.1111/j.1365-2982.2010.01620.x. PubMed DOI

Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141:599–609.e3. doi: 10.1053/j.gastro.2011.04.052. PubMed DOI

Ravelli KG, Rosário B dos A, Camarini R, Hernandes MS, Britto LR. Intracerebroventricular streptozotocin as a model of Alzheimer’s disease: neurochemical and behavioral characterization in mice. Neurotox Res. 2016;31:327–333. doi: 10.1007/s12640-016-9684-7. PubMed DOI

Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015:5.47.1, 5.47.20 Available from: 10.1002/0471141755.ph0547s70. PubMed

Walker J, Harrison F. Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer’s disease: impacts on cognitive decline. Nutrients. 2015;7:7332–7357. doi: 10.3390/nu7095341. PubMed DOI PMC

Davari S, Talaei SA, Alaei H, Salami M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome–gut–brain axis. Neuroscience. 2013;240:287–296. doi: 10.1016/j.neuroscience.2013.02.055. PubMed DOI

Desbonnet L, Clarke G, Shanahan F, Dinan TG, Cryan JF. Microbiota is essential for social development in the mouse. Mol Psychiatry. 2013;19:146–148. doi: 10.1038/mp.2013.65. PubMed DOI PMC

Desbonnet L, Clarke G, Traplin A, O’Sullivan O, Crispie F, Moloney RD, et al. Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav Immun. 2015;48:165–173. doi: 10.1016/j.bbi.2015.04.004. PubMed DOI

Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21 Available from: 10.1186/s13054-017-1856-1. PubMed PMC

Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer’s disease. J Neurol. 2009;256:758–767. doi: 10.1007/s00415-009-5011-z. PubMed DOI

Yulug B, Hanoglu L, Ozansoy M, Isık D, Kilic U, Kilic E, et al. Therapeutic role of rifampicin in Alzheimer’s disease. Psychiatry Clin Neurosci. 2018;72:152–159. doi: 10.1111/pcn.12637. PubMed DOI

Budni J., L. Garcez M., de Medeiros J., Cassaro E., Bellettini-Santos T., Mina F., Quevedo J. The Anti-Inflammatory Role of Minocycline in Alzheimers Disease. Current Alzheimer Research. 2016;13(12):1319–1329. doi: 10.2174/1567205013666160819124206. PubMed DOI

Wang C, Yu J-T, Miao D, Wu Z-C, Tan M-S, Tan L. Targeting the mTOR signaling network for Alzheimer’s disease therapy. Mol Neurobiol. 2013;49:120–135. doi: 10.1007/s12035-013-8505-8. PubMed DOI

Portero-Tresserra M, Martí-Nicolovius M, Tarrés-Gatius M, Candalija A, Guillazo-Blanch G, Vale-Martínez A. Intra-hippocampal d-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats. Psychopharmacology (Berl). 2018;235(5):1463–1477. doi: 10.1007/s00213-018-4858-z. PubMed DOI

Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156(3):467–469. PubMed

Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J Am Geriatr Soc. 2004;52:381–387. doi: 10.1111/j.1532-5415.2004.52109.x. PubMed DOI

Molloy DW, Standish TI, Zhou Q, Guyatt G. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer’s disease: the DARAD trial. Int J Geriatr Psychiatry. 2012;28:463–470. doi: 10.1002/gps.3846. PubMed DOI

Jones R, Laake K, Øksengård AR. D-cycloserine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002; Available from: 10.1002/14651858.cd003153. PubMed PMC

Richardson A, Galvan V, Lin A-L, Oddo S. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol. 2015;68:51–58. doi: 10.1016/j.exger.2014.12.002. PubMed DOI PMC

Pistollato F, Iglesias RC, Ruiz R, Aparicio S, Crespo J, Lopez LD, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: a focus on human studies. Pharmacol. Res. 2018. PubMed

Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013. PubMed PMC

Akbari E, Asemi Z, Kakhaki RD, Bahmani F, Kouchaki E, Tamtaji OR, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016. PubMed PMC

Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F, et al. Lactobacillus and bifidobacterium ameliorate memory and learning deficits and oxidative stress in Aβ (1-42) injected Rats. Appl Physiol Nutr Metab. 2018. PubMed

Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, et al. Exercise and probiotics attenuate the development of Alzheimer’s disease in transgenic mice: role of microbiome. Exp Gerontol. 2019. PubMed

Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, et al. Prebiotic effect of Fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis. Front Aging Neurosci. 2017. PubMed PMC

Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science (80- ) 2018;362:776–780. doi: 10.1126/science.aau5812. PubMed DOI

Yang B-G, Hur KY, Lee M-S. Alterations in gut microbiota and immunity by dietary fat. Yonsei Med J. 2017;58:1083. doi: 10.3349/ymj.2017.58.6.1083. PubMed DOI PMC

Hillemacher T, Bachmann O, Kahl KG, Frieling H. Alcohol, microbiome, and their effect on psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018;85:105–115. doi: 10.1016/j.pnpbp.2018.04.015. PubMed DOI

Savin Z, Kivity S, Yonath H, Yehuda S. Smoking and the intestinal microbiome. Arch Microbiol. 2018;200:677–684. doi: 10.1007/s00203-018-1506-2. PubMed DOI

Kaczmarek JL, Thompson SV, Holscher HD. Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health. Nutr Rev. 2017;75:673–682. doi: 10.1093/nutrit/nux036. PubMed DOI PMC

Effect of a Vegan Diet on Alzheimer's Disease

Movement as a Positive Modulator of Aging

Evidences for a Role of Gut Microbiota in Pathogenesis and Management of Epilepsy

Neuroinflammation in Alzheimer's Disease

Multi-pathogen infections and Alzheimer's disease

Administration of pre/probiotics with conventional drug treatment in Alzheimer's disease